Amanda Wanyana is a Ugandan medical doctor who attained her degree in 2013 at Makerere University, Kampala, Uganda.
From 2013 to 2018, she was employed by the Joint Clinical Research Centre (JCRC), Lubowa, Uganda where she was involved in clinical management and research of people living with HIV. She participated in a major international randomized phase III clinical Strategic Timing of Antiretroviral Therapy (START) trial which informed WHO’s ‘Test and Treat’ approach to HIV management.
From 2018 to date, she has been working with the Uganda Virus Research Institute- International AIDS Vaccine Initiative (UVRI-IAVI) HIV vaccine program. She participated in a multi-center sub-Saharan randomized HPTN 084 phase III clinical trial in women who recently demonstrated the superiority of long acting injectable Cabotegravir as pre-exposure prophylaxis (PREP) against HIV as compared to oral Truvada.
In June 2021, she begun a new journey as a an EDCTP-TDR Clinical Research and Development Fellow at the European Vaccine Initiative (EVI) in Germany funded by WHO-TDR. The focus of her hands-on training will be vaccine development and project management. She looks forward to multi-disciplinary exposure and networking during her apprenticeship with EVI.